Yorumları: 46
Konuları: 0
Kayıt Tarihi: 11-12-2018
Rep Puanı:
0
Cinsiyet: Erkek
Yok yaptırdıktan en az 1 ay ile 3 ay arası hamile kalmaman gerekiyo
Yorumları: 69
Konuları: 4
Kayıt Tarihi: 13-04-2019
Rep Puanı:
3
Cinsiyet: Erkek
V-VAX'ten haber var!
JUPITER, FL, July 23, 2019. X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it has raised $56 million in an upsized Series A financing with participation from strategic and institutional investors, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; and FF DSF VI, a scout investment vehicle out of Founders Fund. Proceeds from the financing will be used to advance X-VAX’s lead program, a vaccine candidate against herpes, called ∆gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study.
“We are pleased to have the support of our new and existing investors as we continue to build our leadership position in the development of a herpes vaccine,” said Ulf Wiinberg, President and Chief Executive Officer of X-VAX. “We are encouraged by the preclinical data for our new approach to beating herpes and creating a potentially world-changing vaccine.”
“Herpes infections are a significant global health problem that affect all age groups from infants to the elderly. Infection is associated with a wide range of disease,” said Betsy Herold, MD, co-Inventor and Professor of Pediatrics, Microbiology & Immunology at Albert Einstein College of Medicine in New York. “The ability of the virus to successfully escape clearance by the immune system and to establish a non-replicating state known as latency with periodic reactivation results in lifelong infection and ongoing risk of transmission.”
“We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity,” added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine.
Yorumları: 10
Konuları: 1
Kayıt Tarihi: 23-08-2018
Rep Puanı:
0
Cinsiyet: Erkek
Yani diyorki x -vax bir finansman aldı güzel bir miktar böylece faz 1 klinik testlere başlayacak diğer aşılardan farklı olması x-vax herpesin bağışıklık sistemimizden kaçmasını sağlayan protein olan gd2 yi herpes ten temizleyip tekrar vücutta verip antikorlar sayesinde hastalığı vucut dan temizlemek yani zayıflatılmış herpes